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Abstract
Background: Cylicodiscus gabunensis Harms (Family Leguminosae) (CG) is an African medicinal plant used as a
treatment of various ailments including malaria, liver diseases, and gastrointestinal disturbances. Its extracts showed
potent in vitro antibacterial activity. However, the antibacterial components are unknown.
Methods: In this study, the stem bark of the CG plant was extracted and its antibacterial property against a panel of
Gram-negative and Gram-positive bacterial strains assessed using the disk diffusion assay method. Bioassay-guided
fractionation of the bioactive extracts was employed to identify bioactive constituents using both gas and liquid
chromatography mass spectrometry. Chemical synthesis was used to make the analogues of gallic acid. Microplate
dilution assays and scanning electron microscopy (SEM) were used to evaluate the antibacterial properties and
mechanism of action of the active fractions and pure compounds.
Results: The most bioactive sub-fractions derived from CG comprised of ethyl gallate, gallic acid and polyphenols. Five
alkyl/alkenyl gallates were synthesized. A preliminary structure-activity relationship of gallic acid derivatives was obtained
using the synthetic analogues and a series of commercially available phenolic compounds. Increasing the length of alkyl
chains generally increases the potency of the alkyl gallates. Introducing a double bond with restricted conformations of
the C-5 side chain has little effect on the antibacterial property. SEM analysis of the effect of alkyl gallates on
Staphylococcus aureus indicates that they appear to interrupt S. aureus bacterial cell wall integrity.
Conclusions: The results of this research rationalise the ethnobotanical use of C. gabunensis and suggest that gallate
derivatives may serve as promising antibacterial agents for the treatment of infectious diseases.
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Background
Plants have been used by mankind to satisfy their medi-
cinal needs from time immemorial. The plant kingdom
produces a diverse range of secondary metabolites with a
plethora of chemical scaffolds that have been optimized to
possess biological activity [1]. About 120 plant-derived
active compounds are medically in use, comprising about
25% of the globally prescribed drugs. Furthermore, 11% of
the total 252 drugs in the WHO’s essential medicine list
by 2011 are of plant origin [2]. In the process of drug dis-
covery, plant screening based on ethno-pharmacological
claims has been reported with a high success rate [1]. Sec-
ondary metabolites from medicinal plants have been
shown to be a good source of antimicrobials when used
alone or in combination with antibiotics to fight life
threatening microbes [3–5].
Cylicodiscus gabunensis Harms (CG) (Leguminosae) is
an indigenous medicinal plant widely distributed in West
and Central Africa. Its bark extract has been used as an
analgesic, antipyretic, anti-inflammatory herbal drug, and
for the treatment of jaundice and malaria by the Ibibio of
Niger Delta region of Nigeria [6, 7]. Aqueous CG extracts
have recently showed antioxidant and anti-diabetic
properties [8, 9]. So far, triterpenes such as cylicodiscic
acid [10], triterpenoid saponins [11–13], cyclodione [14],
and coumestan glycosides [15] have been isolated and
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identified from this plant. We have recently characterized
the most antimalarial components of CG extracts as a
mixture of phenolic acid and polysaccharide conjugates
[16] providing evidence for its use by the Ibibio people of
Nigeria as antimalarial remedy [17]. The ethyl acetate ex-
tract from CG also shows broad antibacterial activities
against several clinical isolates such as Escherichia coli,
Staphylococcus aureus, and Pseudomonas aeruginosa
[7]; however, the source of these antibacterial activities
have not yet been determined. In continuation of our
search for antibacterial agents from natural resources
[18–20], here we report the bioassay-guided fraction-
ation, isolation, identification, synthesis, and evaluation
of antibacterial activity of compounds from CG bark
extract. A systematic study of the structure activity
relationship of synthetic and commercially available
alkyl gallates was also carried out.
Methods
Plant materials and chemicals
C. gabunensis stem bark was collected in September
2012 from the woods of Imo state, Nigeria and authenti-
cated by H. Donyeachusim, a taxonomist in the Univer-
sity of Port Harcourt, Nigeria. A voucher specimen is
deposited in the University of Port Harcourt, Nigeria
(UPH1028). All the solvents used in this study supplied
by Fischer Scientific, UK are of high analytical grade and
HPLC grade when used for chromatography. 3,4,5-trihy-
droxybenzoic acid (gallic acid, 1); 3,4-dihydroxybenzoic
acid (protocatechuic acid, 2); 4-hydroxy-3-methoxyben-
zoic acid (vanillic acid, 3); 4-hydroxy-3,5-dimethoxyben-
zoic acid (syringic acid, 4); 3,4,5-trimethoxybenzoic acid
(5); ethyl 3,4,5-trihydroxybenzoate (ethyl gallate, 6);
propyl 3,4,5-trihydroxybenzoate (propyl gallate, 7); and
dodecyl 3,4,5-trihydroxybenzoate (lauryl gallate, 13) were
purchased from Sigma Aldrich UK.
Preparation of extracts and fractions
The extraction of CG bark (120 g) was done according
to a general procedure [21] for the extraction of
secondary metabolites such as saponins which were
previously reported in this plant [11–13]. The plant
bark powder was first defatted using hexane to give
the nonpolar hexane extract (CGH, 0.9 g, 0.75% w/w). The
residue was extracted again using 70% ethanol twice to
give the polar ethanol extract (CGE, 11.3 g, 9.4% w/w)
(Additional file 1: Figure S1) [16]. CGE was further
partitioned in water with ethyl acetate and n-butanol
sequentially [21] to give the ethyl acetate fraction
(CGEEA, 0.9 g, 8% w/w), butanol fraction (CGEBU,
8.3 g, 77% w/w) and aqueous fraction (CGEAQ, 1.6 g,
15% w/w).
Purification and fractions of CGEEA fraction
The CGEEA fraction (0.85 g) was fractionated on a silica
gel column (35–75 μm; 2.5 × 50 cm) eluting with hexane:
ethyl acetate (4:1), ethyl acetate and finally methanol.
Each fraction was 100 mL and 18 fractions were
collected. The detection of eluates was performed using
thin layer chromatography (SiO2, the solvent system is a
mixture of hexane and ethyl acetate (3:2)) and visualized
under UVGL-25 compact UV lamp at 254/365 nm. All
the fractions were checked by TLC and the fractions
with similar compound patterns were combined and
dried at 45 °C under vacuum, yielding 8 combined frac-
tions, CGEEA-F1-8: F1, 29 mg; F2, 9.1 mg; F3, 8.8 mg;
F4, 8.9 mg; F5, 450 mg; F6, 130 mg; F7, 72.3 mg; and F8,
97.2 mg.
Purification of CGEEA-F5 using high performance liquid
chromatography
An Agilent 1200 series high performance liquid chroma-
tography (HPLC) system consisting of G2258A DLA
dual loop auto-sampler and G1361A preparative pump
were used for the further purification of CGEEA-F5
(0.42 g) using a X bridge C18 Prep column (5 μm, 19
mm × 100mm) and monitored at 254 nm using a Waters
G1315D DAD Diode Array Detector. Solvents (A: 0.1%
v/v glacial acetic acid in water, B: 0.1% v/v glacial acetic
acid in methanol) were used at a flow rate of 16 mL/min
and a max pressure of 400 bar. A gradient of A and B
solvent system (5% B for 5 min; 5–60% B over 25 min;
and 100% B for 6 mins) was used. Twelve sub-fractions
(CGEEA-F5-(1 to 12)) were collected and lyophilized to
give: F1, 12 mg; F2, 2 mg; F3, 2 mg; F4, 2 mg; F5, 2 mg;
F6, 4 mg; F7, 16 mg; F8, 21 mg; F9, 83 mg; F10, 223 mg;
F11, 13 mg; and F12, 8 mg.
Gas chromatography mass spectrometry
The chemical constituents of CGEEA-F5, CGEEA-F5–
8 and synthetic gallate derivatives (8–12) after deriv-
ing into their corresponding trimethylsilyl (TMSi)
derivatives were characterized using gas chromatog-
raphy mass spectrometry on HP5-MS column as pre-
viously described [16, 22].
Time-of-flight liquid chromatography mass spectrometry
(TOF LC-MS)
The Infinity 1260 series system comprises a G4225A
Hip Degasser, G1312B Binary Pump, G1329B ALS Auto
sampler, G1316A TCC Thermostated column compart-
ment, HyPURITY C8 column (50 × 2.1 mm, particle size
5 μm) from Thermo Fisher Scientific, UK and 6530
Accurate Mass Q-TOF as the detector. Qualitative ana-
lysis Mass Hunter work station software, ion Source
Dual ESI, ion Polarity positive, a detector with mass
range 100–1700 m/z were used throughout. A flow rate
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of solvent (A: 0.1% formic acid in water, B: acetonitrile)
was kept at 0.5 ml/min with a gradient of keeping 5% B
over 10 min and increasing from 5 to 95% from 10 to
18min. Molecular formulae were generated using high
resolution mass by consideration of likelihood of the
unsaturation degrees using Mass Hunter work station
software. The putative identification of polyphenols
(Table 2) was performed by searching the obtained mo-
lecular formula against the ChemSpider database of the
Royal Society of Chemistry (http://www.chemspider.
com) and Reaxy database (www.reaxy.com).
Analysis of CGEEA-F5 and CGEEA-F5–8 by analytical HPLC
Analysis of CGEEAF-5 and CGEEAF-5-8 was carried out
using a linear gradient from 10 to 70% B over 25 mins and
keeping 100% B for 6 mins, where A was water and B
methanol on an analytical HPLC column (Phenom-
enex, UK; Jupiter C18 reverse phase column, 300 A,
5 μm particle size, 4.6 mm × 250 mm) at a flow rate of
1 mL/min. Gallic acid and ethyl gallate were used as
internal standards.
Synthesis of alkyl and alkenyl 3, 4, 5-trihydroxybenzoates
(gallic acid derivatives)
A general procedure of synthesis of gallate derivatives
(8–12) was based on a previous report [16, 30] and
described as follows with modification. To a solution of
gallic acid (3.0 mmol; 510mg) and anhydrous alcohols
(i.e. isopropanol, 2-methylpropanol, 2-methylbutanol, 3-
methylbutanol, or 3-methylbutenol, each 4.0 mmol) in
tetrahydrofuran (THF) (6 ml) in an ice bath at 0 °C, a so-
lution of N,N-dicyclohexylcarbodiimide (DCC) (3.5
mmol, 720 mg) in THF (6 ml) was added. The mixture
was allowed to stir for 24 h, and was evaporated under
vacuum. The product, a dark yellow residue, was extracted
with cold ethyl acetate three times. The upper layers were
combined and evaporated. The synthesized esters were
purified using silica gel column chromatography (35–
75 μm; 4 × 30 cm) by eluting with hexane: ethyl acetate (7:
3, isocratic) at a flow rate of 3 ml/min. The eluates were
subjected to thin layer chromatography (silica gel, ethyl
acetate: hexane 7: 3) and visualised under a UV lamp
(254/365 nm) or exposed to iodine vapour.
Propan-2-yl 3,4,5-trihydroxybenzoate (8, 534 mg,
83%): positive-ion TOF LC-MS, m/z: 235.0576 (calcd.
mass for C10H12NaO5, [M +Na]
+, 235.0582). GC-EI-MS
of TMSi derivative of 8 (Rt, 19.141 min), m/z (%): 428.2
(40), 369.2 (5), 311.1 (6), 281.1 (55), 239.0 (35), 209.0 (5),
179.0 (9), 133.0 (7), 73.1 (100). 1H NMR (400MHz,
CD3OD) δ: 7.06 (2H, s, H-2, 6), 5.09–5.17 (1H, m, H-8),
1.34 (6H, d, J = 6.4 Hz, H-9, 10). 13C NMR (100MHz,
CD3OD) δ: 166.7 (C-7), 145.0 (C-3, 5), 138.2 (C-4), 120.8
(C-1), 108.6 (C-2, 6), 67.8 (C-8), 20.8 (C-9, 10).
2-Methylpropyl 3,4,5-trihydroxybenzoate (9, 583 mg,
85%): positive-ion TOF LC-MS, m/z: 227.0917 (calcd.
mass for C11H15O5, [M+H]
+, 227.0919). GC-EI-MS of
TMSi derivative of 9 (Rt, 20.592min), m/z (%): 442.3 (45),
369.2 (8), 281.1 (55), 239.1 (33), 179.0 (5), 133.0 (5), 73.1
(100). 1H NMR (400MHz, CD3OD) δ: 7.08 (2H, s, H-2,
6), 4.02 (2H, d, J = 6.6 Hz, H-8), 2.04 (1H, dt, J = 13.3, 6.6
Hz, H-9), 1.03 (6H, d, J = 6.6 Hz, H-10, 11). 13C NMR
(100MHz, CD3OD) δ: 167.2 (C-7), 145.1 (C-3, 5), 138.3
(C-4), 120.3 (C-1), 108.6 (C-2, 6), 70.3 (C-8), 27.8 (C-9),
18.1 (C-10, 11).
2-Methylbutyl 3,4,5-trihydroxybenzoate (10, 597mg,
82%): Positive-ion TOF LC-MS, m/z: 241.1073 (calcd. mass
for C12H17O5 [M+H]
+, 241.1076). GC-EI-MS of TMSi
derivative of 10 (Rt, 21.440min), m/z (%): 456.3 (55), 369.2
(8), 311.1 (4), 281.1 (55), 239.0 (25), 179.0 (10), 133.0 (5),
73.1 (100). 1H NMR (400MHz, CD3OD) δ: 7.07 (2H, s, H-
2, 6), 4.02–4.16 (2H, m, H- 8), 1.79–1.87 (1H, m, H-9),
1.45–1.55 (1H, m, H-10), 1.26–1.34 (1H, m, H-10), 1.02
(3H, d, J = 6.8Hz, H-12), 0.95–1.01 (3H, t, H- 11). 13C
NMR (101MHz, CD3OD) δ: 167.2 (C-7), 145.1 (C-3, 5),
138.3 (C-4), 120.3 (C-1), 108.6 (C-2, 6), 68.8 (C-8), 34.3 (C-
9), 25.8 (C-10), 15.5 (C-12), 10.3 (C-11).
3-Methylbutyl 3,4,5-trihydroxybenzoate (11, 604 mg,
83%): positive-ion TOF LC-MS, m/z: 241.1071 (calcd.
mass for C12H17O5, [M +H]
+, 241.1071). GC-EI-MS of
TMSi derivative of 11 (Rt, 21.396 min), m/z (%): 456.3
(55), 369.2 (8), 311.1 (4), 281.1 (55), 239.0 (25), 179.0
(10), 133.0 (5), 73.1 (100). 1H NMR (400MHz, CD3OD)
δ: 7.06 (2H, s, H- 2, 6), 4.27 (2H, t, J = 6.6 Hz, H- 8), 1.64
(2H, q, J = 6.7 Hz, H- 9), 1.25 (1H, m, H- 10), 0.99 (6H,
d, J = 6.6 Hz, H- 11, 12). 13C NMR (100MHz, CD3OD)
δ: 167.2 (C-7), 145.1 (C-3, 5), 138.3 (C-4), 120.3 (C-1),
108.6 (C-2, 6), 62.8 (C-8), 37.3 (C-9), 25.0 (C-10), 21.5
(C-11, 12).
3-Methylbut-2-en-1-yl 3,4,5-trihydroxybenzoate (12,
606 mg, 84%): Positive-ion TOF LC-MS, m/z: 239.0922
(calcd. Mass for C12H15O5, [M +H]
+, 239.0919). GC-EI-
MS of TMSi derivative of 12 (Rt, 21.798 min), m/z (%):
454.2 (35), 386.2 (12), 355.1 (6), 311.1 (4), 281.1 (55),
239.1 (25), 179.0 (10), 133.0 (5), 73.1 (100). 1H NMR
(400MHz, CD3OD) δ: 7.05 (2H, s, H-2, 6), 5.45 (1H,
ddt, J = 8.6, 5.8, 1.4 Hz, H-9), 4.74 (2H, d, J = 7.2 Hz, H-
8), 1.79 (6H, d, J = 2.4 Hz, H-11, 12). 13C NMR (100
MHz, CD3OD) δ: 167.1 (C-7), 145.1 (C-3, 5), 138.6 (C-
10), 138.3 (C-4), 120.4 (C-1), 118.7 (C-9), 108.6 (C-2, 6),
61.0 (C-8), 16.7 (C-11), 24.5 (C-12).
Bacterial strains and growth conditions
Bacterial isolates were supplied by the National Col-
lection of Industrial and Marine Bacteria NCIMB
Ltd., Aberdeen, Scotland. The bacterial isolates used
were Bacillus cereus NCIMB 9945, Bacillus subtilis
NCIMB 3610, Staphylococcus aureus NCIMB 11832,
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Staphylococcus epidermidis NCIMB8853, Enterobacter
cloacae NCIMB 10101, Escherichia coli NCIMB8277,
Alcaligenes faecalis NCIMB 8156, Pseudomonas aeru-
ginosa NCIMB 10848 and Enterococcus faecalis
NCIMB 2707. For the disk diffusion assay, the inocu-
lum density used was 1.5 × 108 CFU/ mL with 100 μL
of inoculum plated on bacterial nutrient broth
(Oxoid, UK).
Disk diffusion assay
Disk diffusion assay (DDA) was run according to the
EUCAST standards [31]. CGH and CGE extracts and
CGEEA, CGEBU and CGEAQ fractions were dissolved
in dimethyl sulfoxide (DMSO). The CGH and CGE
extracts were prepared in four different concentrations
as 100, 50, 25, and 12.5 mg/mL. The CGEEA, CGEBU
and CGEAQ fractions were prepared as 12.5 mg/mL.
20 μL of each preparation were distributed evenly on
Whatman sterile filter paper disks (6 mm, Fischer Scien-
tific, UK) to yield 2.0 mg/disk, 1.0 mg/disk, 0.5 mg/disk,
and 0.25 mg/disk. Two controls were used on each plate;
for the first was the carrier solvent DMSO (final concen-
tration, 3% v/v) as negative control and the second
ampicillin as positive control with an amount of 10 or
2 μg per disk. The disks were applied firmly onto the
surface of the inoculated agar plate, inverted and incu-
bated at 37 °C overnight in a LMS series incubator. The
recorded inhibition zone (IZ) is an indication of the anti-
bacterial activity which increases in size as the potency
of the compound increases. All experiments were carried
out using three biological replicates with the mean IZ
and standard deviation (SD) reported.
Determination of minimum inhibitory concentration
The minimum inhibitory concentrations (MICs) of the
plant extracts and compounds explored in this study
were determined using the microplate Alamar Blue assay
as previously described [32, 33]. The bacterial isolates
were first adjusted to McFarland standard 0.5 (~ 1 × 108
CFU/ml), which were then diluted by adding 0.2 ml bac-
terial suspension to 19.8 ml sterile broth medium (1:100
fold dilution) to give the final bacterial concentration
(1× 106 CFU/ml).
Briefly, 100 μL of each bacterium culture with a bac-
terial density of 1 × 106 CFU/mL was distributed into
each test well and growth control well in black 96-well
microplates (Fischer-Scientific, UK). The tested materials
were dissolved in 6% DMSO (v/v) to provide a ma-
ximum concentration of 3% (v/v) DMSO and a mini-
mum concentration at 0.023% (v/v). Ampicillin was
included as a positive control at a maximum concentra-
tion of 64 μg/mL and a minimum concentration of
0.5 μg/mL. The final concentrations of the extracts/
pure compounds were tested from 8 to 1024 μg/mL.
After 24 h of incubation at 37 °C, 20 μL of Alamar Blue
solution (Fischer Scientific, UK) was added to each well
and the plates incubated for 2–4 h at 37 °C to enable the
colour reaction to develop. A GloMax-plus®-Multi De-
tection System with a fluorescent filter (Ex 525 nm and
Em 580–640 nm) was utilised to determine the fluores-
cence in each well. Data presented represents two tech-
nical replicates as two biological replicates (n = 4). The
following equation was used to calculate the percentage
of inhibition for each drug used: [1 – (FUtest well – FUSC
well) / (FUCG well – FU SC well)] × 100, where FUtest well
represents mean of fluorescence in the absence of ampi-
cillin/extract; FUSC well, mean of fluorescence in the ster-
ility control; FU GC well, mean of fluorescence in growth
in wells with CG extract. The MICs were determined as
the lowest concentration that produced a decrease in
bacterial population by 90% [32].
Scanning electron microscopy
Gallic acid (1), ethyl gallate (6), propan-2-yl 3,4,5-trihy-
droxybenzoate (8), and 2-methylpropyl 3,4,5-trihydrox-
ybenzoate (9) were added separately into 3mL of S.
aureus culture at a concentration that represented 2 ×
MIC (Table 1). The bacterial culture was used at 1.0 × 108
CFU/mL and a carrier solvent control (0.2% DMSO-
treated) sample was studied in parallel. After 1 h of con-
tact with the compounds, the specimens were prepared
for studying by scanning electron microscopy (SEM) as
described [34]. The specimens were coated with a thin
gold film using an Emscope FD 500 sputter coater before
imaging using the Scanning Electron Microscope (Model
S-4500, Hitachi, Japan).
Results
Disk diffusion assay of extracts and fractions
The extraction and bioassay-guided fractionation of CG
was carried out using a scheme reported in Additional
file 1: Figure S1 with the antibacterial activity of the CG
extracts and their fractions initially assayed using the
DDA method (Additional file 1: Figure S2). The polar
extract of CG (CGE) showed more potent activity than
CGH against S. aureus, S. epidermidis, B. cereus, B. sub-
tilis and S. facecalis. CGH showed no effect against S.
epidermidis, B. cereus, B. subtilis and S. facecalis and
only mild effect against S. aureus (Additional file 1:
Tables S1 and S2). The largest IZ for CGE were recorded
as 19.5 ± 1.0 and 16.5 ± 0.5 mm against S. epidermidis
and S. aureus, respectively. The CGEEA, CGEBU, and
CGEAQ all showed moderate to good antibacterial
activities against the gram-positive strains but not the
gram-negative strains except Alcaligenes faecalis
(Additional file 1: Table S1).
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Antibacterial activity of CGEEA fractions and sub-fractions
CGEEA was separated further into eight sub-fractions
using silica gel column chromatography. These sub-
fractions were assayed for their inhibition of six bacterial
species against which CGEEA had shown the most po-
tent activity in the DDA assays (data not shown).
Fraction 5, termed CGEEA-F5, was the most active frac-
tion (Table 1). Preparative HPLC (Additional file 1:
Figure S3) was used to separate fraction CGEEA-F5
into 12 further fractions, which were also tested
using the microdilution assay. Sub-fraction 8, termed
CGEEA-F5–8, was the most active sub-fraction, showing
improved potency against S. aureus and S. epidermis with
MICs of 128 and 64 μg/ml, respectively (Table 1 and Add-
itional file 1: Table S3).
Characterisation of bioactive compounds
CGEEA-F5 (Additional file 1: Figure S4) and CGEEA-
F5–8 (Additional file 1: Figure S5 and S6) were charac-
terized by gas chromatography mass spectrometry
(GC-MS). A number of fatty acids, sugars, and phenolic
derivatives such as gallic acid (1), syringic acid (4), and
ethyl gallate (6) (Fig. 1, Additional file 1: Table S4) were
identified in CGEEA-F5. GC-MS analysis of CGEEA-
F5–8 revealed the presence of abundant ethyl gallate
(6), with only traces of gallic acid and syringic acid
(Additional file 1: Figure S5 and S6). The presence of
these components was confirmed using analytical
HPLC with commercially sourced materials as stan-
dards (Additional file 1: Figure S7). Liquid chroma-
tography electrospray ionization high resolution mass
spectrometric (ESI-MS) analysis of CGEEA-F5–8 fur-
ther confirmed the presence of ethyl gallate and syrin-
gic acid (Additional file 1: Figure S8). Several other
compounds with high molecular weights were tentatively
identified as 3-(4-hydroxybenzoyl)epicatechin, phenolic
glycosides, and condensed tannins (proanthocyanidins)
(Table 2) by high resolution mass spectrometry and 1H
NMR spectroscopy (Additional file 1: Figure S9). These
compounds were unlikely detected using GC-MS due to a
mass limit (1050 Da) of detection and low volatility of
their TMSi derivatives.
Antibacterial activity of isolated and synthetic phenolic
compounds
To gain structure activity relationship of gallate and alkyl
gallate derivatives, five gallate analogues (8–12) were
synthesized. The MICs of gallic acid (1), ethyl gallate (6),
the synthetic (8-12) and commercially available (2–5,
13) gallate analogues (Table 1, Fig. 1) were determined.
Ethyl gallate (6) is more potent than gallic acid in all of
the six bacteria species tested. In particular, 6 showed
potency against S. epidermidis and E. coli. However, it
showed less potency against S. aureus than S. epidermi-
dis, whilst CGEEA-F5–8, containing both ethyl gallate
and gallic acid, showed strong inhibition. This may be
that additional polyphenols are more active, or potenti-
ate the activity of ethyl gallate and/or gallic acid.
The effect of alkyl gallates was more pronounced against
both S. aureus and S. epidermidis species tested. S. epider-
midis was more sensitive to the compounds used, with the
order of activity as follows: vanillic acid (3), syringic acid
Table 1 The MIC (μg/ml) of CG sub-fractions, synthetic and commercially sourced gallate derivatives against a panel of six bacteria
Fractions/pure compound S. aureus S. epidermidis E. coli B. subtilis B. cereus A. faecalis
CGEEA-F5 256 128 1024 > 1024 1024 256
CGEEA-F5–8 128 64 512 NA NA 128
3,4,5-Trihydroxybenzoic acid (gallic acid, 1) 2000 500 1000 1000 1000 1000
3,4-Dihydroxybenzoic acid (2) 1000 500 1000 1000 1000 500
4-Hydroxy-3-methoxybenzoic acid (3) 1000 1000 1000 1000 1000 500
4-Hydroxy-3,5-dimethoxybenzoic acid (4) 1000 1000 500 1000 2000 500
3,4,5- Trimethoxybenzoic acid (5) 1000 1000 1000 1000 1000 500
Ethyl 3,4,5-trihydroxybenzoate (ethyl gallate, 6) 1000 250 62.5 1000 1000 250
Propyl 3,4,5-trihydroxybenzoate (7) 500 250 125 1000 1000 250
Propan-2-yl 3,4,5-trihydroxybenzoate (8) 1000 250 62.5 >1000 >1000 250
2-Methylpropyl 3,4,5-trihydroxybenzoate (9) 500 250 500 1000 1000 500
2-Methylbutyl 3,4,5-trihydroxybenzoate (10) 250 250 250 250 500 250
3-Methylbutyl 3, 4, 5-trihydroxybenzoate (11) 250 250 250 250 500 500
3-Methylbut-2-en-1-yl 3,4, 5-trihydroxybenzoate (12) 250 250 500 500 1000 500
Dodecyl 3,4,5-trihydroxybenzoate (lauryl gallate, 13) 8 8 >1000 31.25 31.25 1000
Ampicillin ≤0.5 ≤0.5 ≤0.5 ≤0.5 >64 16
NA not assayed
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(4), and 3,4,5-trimethoxybenzoic acid (5) < gallic acid (1),
protocatechuic acid (2) < ethyl gallate (6), propyl gallate
(7), isopropyl gallate (8), 9–12 < lauryl gallate (13). Strik-
ingly, lauryl gallate (13) showed the most potent effect
against both S. aureus and S. epidermidis (MIC ≤8 μg/ml).
These results suggest that the alkyl chain length of
these gallate derivatives is an important factor con-
tributing to the antibacterial activities against S. aur-
eus and S. epidermidis. In general, the phenolic
hydroxyls show the same, or reduced potency against
S. aureus compared to S. epidermidis.
Scanning electron microscopy
Scanning electron microscopy (SEM) was used to study
the ultrastructure of S. aureus cell wall integrity follow-
ing exposure to gallic acid (1), ethyl gallate (6), propan-
2-yl 3,4,5-trihydroxybenzoate (8) and 2-methylpropyl 3,
4,5-trihydroxybenzoate (9).
For all of these phenolics, when compared to an un-
treated control (Fig. 2a), all treatments affected S. aureus
cell wall integrity (Fig. 2b-e) with evidence of loss of cell
shape and leakage of cytoplasmic content onto the sur-
face of the bacteria.
Propan-2-yl 3,4,5-trihydroxybenzoate (8) and 2-
methylpropyl 3,4,5-trihydroxybenzoate (9) appear to
cause a more prominent effect (Fig. 2d-e) with a greater
proportion of damaged S. aureus evident and more
evidence of extruded cytoplasmic material, when com-
pared to gallic acid and ethyl gallate. As such, these
SEM data support that alkyl gallates are apparently more
potent in agreement with the MIC data (Table 1).
Esterification of gallic acid with alkyl group with five and
twelve carbon chains (10, 11, and 13) also increased the
antibacterial activity against B. cereus and B. subtilis com-
pared to gallic acid and other alkyl gallates with shorter
carbon chains (Table 1). 3-Methylbut-2-en-1-yl 3,4,5-trihy-
droxybenzoate (12) with a double bond with restriction of
the conformational change of the side chain led to a 2-fold
decrease of the antibacterial effect against E. coli, B. cereus
and B. subtilis compared to 3-methylbutyl 3,4,5-trihydroxy-
benzoate (11), but no effect on other bacteria tested. Lauryl
gallate (13) also showed more potent activity against B. ce-
reus and B. subtilis. However, in a reverse of this trend,
ethyl gallate (6) and isopropyl gallate (8) were more potent
against E. coli than lauryl gallate (13).
Discussion
Previously, the antibacterial activity of CG extracts was
evaluated. However, the bioactive constituents responsible
for the observed biological activity are unknown [7].
CGEEA was the most potent among the CGE sub-
fractions, in agreement with the previous report [7] with
the exception of P. aeruginosa shown as inactive here.
Our results demonstrated the presence of various phen-
olic compounds including gallate derivatives and complex
polyphenols in the CG extracts using bioassay-guided
fractionation, GC-MS, LC-MS and NMR characterization.
Gallic acid, ethyl gallate and alkyl gallates were also
Fig. 1 Chemical structure of gallic acid derivatives isolated from C. gabunensis, synthetic and commercially available gallate derivatives used in
this study
Aldulaimi et al. BMC Complementary and Alternative Medicine          (2019) 19:183 Page 6 of 11
Table 2 Tentative identification of compounds detected from CGEEA-F5–8 by LC-MS/MS using on-line ChemSpider database
(http://www.chemspider.com) and Reaxys database (https://www.reaxys.com)
RT
(min)
Molecular
Formula
Molecular
mass
Found [M +
H]+ m/z
Name of compound Chemical structure Reference
2.36 C7H6O5 170.0214 171.0287 Gallic acid (1) [16]
2.36 C9H10O5 198.0528 199.0603 Ethyl gallate (6) [16]
3.07 C20H22O9 406.1265 407.1338 Trans-3,5,3′,4′-tetrahydroxystilbene-3-O-β-D-
glucopyranoside
[23]
3.44 C22H26O13 498.1373 499.1446 3,4,5-Trimethoxyphenyl 6-O-(3,4,5-trihydroxyben-
zoyl)-β-D-glucopyranoside
[24]
3.45 C22H18O8 410.1001 411.1074 3-(4-Hydroxybenzoyl)epicatechin [25]
3.68 C37H30O14 698.1639 699.1713 Epicatechin-(4β→ 8)-catechin-3-O-(4-
hydroxy)benzoate
[26]
3.72 C37H30O15 714.1585 715.1658 Epiafzelechin-(4β→ 8)- epicatechin-3-O-gallate [27]
3.86 C45H38O16 834.2151 835.2223 Procyanidin C-1 [28]
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found to have anti-plasmodial activity in our previous
study [16]. Surprisingly, no previously reported triter-
penoids [10] and saponins [11–13] were found in
these antibacterial fractions.
There have been a number of studies describing the
antibacterial and antifungal effect of alkyl gallates [30,
35, 36]. The esterification of gallic acid also increases
antifungal activity, with MIC of 12.5 μg/ml for lauryl
(C-12) gallate (13) where both the alkyl group and
catechol or pyrogallol groups are essential for this an-
tifungal activity [30]. Lauryl gallate (13) exhibits bac-
tericidal activity against methicillin resistant S. aureus
(MRSA) strains, with the minimum bactericidal con-
centration of 25 μg/mL due to its ability to inhibit re-
spiratory electron transport systems [37]. Our results
showed that lauryl gallate has weak effect against E.
coli and this could be attributed to the nature of the
gram-negative E. coli cell wall composed of an outer
membrane containing lipopolysaccharides, a periplas-
mic space with a peptidoglycan layer which may pre-
vent penetration of the highly non-polar lauryl gallate.
Alkyl (C-4 and C-5) gallates at concentrations lower
than their MIC effectively increased the sensitivity of
oxacillin against MRSA [38], with the amphiphilic
properties of alkyl gallates enabling them to interact
with the S. aureus cell wall. The galloyl moiety plays
a key role in β-lactam activity intensification. The
structure of the alkyl gallates enables them to interact
with many targets in the bacterial cell wall, which
disrupts the structure of the cell wall and renders the
process of cell wall synthesis inefficient. Of note is
that octyl gallate, with a C-8 alkyl chain length, sig-
nificantly increased the antimicrobial activity of baci-
tracin against multiple drug resistant S. aureus [38].
The gram-positive and sphere–shaped S. aureus bac-
teria were selected for the study on the morphologic ef-
fect of gallic acid and its analogues. It is the most
dangerous of all the staphylococcal bacteria which can
cause skin, bloodstream, lung, and medical implant
infections, endocarditis, and osteomyelitis [39]. Gallic
acid and ethyl gallate are both shown here to apparently
affect the permeability of the S. aureus cell wall, with
extrusion of cell contents leading to an apparent collapse
in cell shape. The effect of gallic acid appears more
prominent than that of ethyl gallate within the first hour
of incubation, consistent with previous finding [40].
Binding to lipids by the alkyl gallates generally increases
with increasing alkyl chain length. Self-association and
membrane binding of the alkyl gallates might therefore
be primary factors associated with their antibacterial
activities [41]. Alkyl gallates also disrupt the cell division
protein FtsZ-ring in B. subtilis cells, resulting in cell
elongation. In vitro, alkyl gallates cause FtsZ protein to
cluster and lose its capacity to polymerize through their
Table 2 Tentative identification of compounds detected from CGEEA-F5–8 by LC-MS/MS using on-line ChemSpider database
(http://www.chemspider.com) and Reaxys database (https://www.reaxys.com) (Continued)
RT
(min)
Molecular
Formula
Molecular
mass
Found [M +
H]+ m/z
Name of compound Chemical structure Reference
3.67 C45H38O17 850.2104 851.2177 Epicatechin--(4β→ 8)-epicatechin--(4β→ 8)-
catechin trimer
[29]
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very tight binding to FtsZ. They also target B. subtilis
membrane integrity [42]. Our results share some agree-
ments with these findings. These novel alkyl (C-4 and C-
5) gallates can effectively disrupt the cell wall integrity of
S. aureus, which may offer a potentially exploitable syn-
ergistic activity with some antibiotics to target resistant
bacterial cells with impermeable cell wall or efflux pump
proteins. Plant-derived polyphenols have been shown to
inhibit bacterial growth [43] and formation of biofilms,
an important factor causing antibacterial resistance [4].
Therefore, the presence of various polyphenols in the
most active fraction should also contribute to its overall
antibacterial activity.
Conclusion
In summary, bioassay-guided fractionation of C. gabu-
nensis bark extract yielded an active antibacterial frac-
tion. Using GC-MS, LC-MS and NMR techniques, gallic
acid (1) and ethyl gallate (6) and other putative polyphe-
nols were identified and likely contributed to the anti-
bacterial activity of C. gabunensis extract. Synthesis of
four alkyl gallates and an alkenyl gallate was carried out.
Preliminary SAR of gallate derivatives indicates that in-
creasing the length of the alkyl chain of alkyl gallate gen-
erally increases their antibacterial potency. The results
of this study support the ethnobotanical use of C. gabu-
nensis and suggest that ethyl gallate and other polyphe-
nols be potential antibacterial agents.
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Fig. 2 Scanning electron micrographs (SEM) of S. aureus exposed to gallate derivatives. a) Control SEM of S. aureus cells after exposure to 0.2%
DMSO for 1 h with arrows pointing to cells undergoing binary fission. SEM of S. aureus cells after exposure to 2 ×MIC level of b) gallic acid (1), c)
ethyl gallate (6), d) propan-2-yl 3,4,5-trihydroxybenzoate (8), and e) 2-methylpropyl 3,4,5-trihydroxybenzoate (9). For panels B to E arrows point to
apparent extrusion of cytoplasmic content from collapsed S. aureus
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